melanotic melanoma Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features True Amelanotic melanoma: the great

Bicinchoninic acid (BCA) protein assay kit (Beyotime Institute of Biotechnology) was used to determine the protein concentration, with bovine serum albumin as the standard

CheckMate 238 (NCT02388906) compared nivolumab with ipi10 and found that nivolumab produced superior RFS and had a more tolerable safety profile.[20] Pembrolizumab produced superior RFS compared with placebo, with data on OS still maturing in the MK-3475-054/KEYNOTE-054 trial (NCT02362594).[21] Dabrafenib plus trametinib produced superior RFS compared with placebo, with data on OS still maturing in the COMBI-AD trial (NCT01682083).[22] Single-agent BRAF-inhibitor therapy with vemurafenib did not show improved RFS compared with placebo in the BRIM8 trial (NCT01667419).[23] The benefit of immunotherapy with ipilimumab, nivolumab, and pembrolizumab has been seen regardless of programmed death-ligand 1 (PD-L1) expression or the presence of BRAF pathogenic variants

As investigational or unlicensed agents, their use during pregnancy or whilst breastfeeding is not recommended

Additionally, data suggests that Ipamorelin may have raised levels of serum leptin, a hormone implicated in regulating energy and appetite